SCHEMBL5467715

SCHEMBL5467715

CCOC(=O)CCCCCOc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
CRHBP P24387 1/20 0.67
CRHR2 Q13324 1/20 0.67
ALDH1A1 P00352 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
HRH2 P25021 1/20 0.54
HRH1 P35367 1/20 0.54
KMT2A Q03164 4/20 0.54
MAPK1 P28482 1/20 0.54
BCL9 O00512 1/20 0.52
CTNNB1 P35222 1/20 0.52
PTGS2 P35354 1/20 0.52
MEN1 O00255 1/20 0.52
KDM4E B2RXH2 1/20 0.52
KCNH2 Q12809 2/20 0.51
HRH3 Q9Y5N1 1/20 0.50
MAOB P27338 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245527 0.99 MAPT (0.68) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL6335807 0.94 MAPT (0.66) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL6024458 0.91 ALDH1A1 (0.62) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL8484284 0.90 MAPT (0.64) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL17888638 0.88 MAPT (0.59) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL16261807 0.88 MAPT (0.56) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL831165 0.88 MAPT (0.56) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL7640264 0.86 MAPT (0.67) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL831490 0.86 PTGS2 (0.58) MAPTL3MBTL1CRHBPCRHR2ALDH1A1
SCHEMBL18689537 0.86 PTGS2 (0.58) MAPTL3MBTL1CRHBPCRHR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012170827-A2 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
WO-2012170827-A2 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2012-12-13 WO disclosed
US-20070178544-A1 Anti fk778antibodies and high sensitive immunoassay methods TAMURA KOUICHI 2007-08-02 US disclosed
EP-1723179-A1 ANTI FK778 ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS Astellas Pharma Inc. (JP) 2006-11-22 EP disclosed
EP-1196545-B1 ELECTRON DONOR SYSTEM FOR ENZYMES AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF SUBSTRATES BASF AG (DE) 2006-10-11 EP disclosed
WO-2005085290-A1 ANTI FK778ANTIBODIES AND HIGH SENSITIVE IMMUNOASSAY METHODS ASTELLAS PHARMA INC. (JP) 2005-09-15 WO disclosed
EP-1196545-A1 ELECTRON DONOR SYSTEM FOR ENZYMES AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF SUBSTRATES BASF AKTIENGESELLSCHAFT (DE) 2002-04-17 EP disclosed
WO-2001007573-A1 ELECTRON DONOR SYSTEM FOR ENZYMES AND ITS USE FOR THE BIOCHEMICAL CONVERSION OF SUBSTRATES BASF AKTIENGESELLSCHAFT (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070178544-A1 Anti fk778antibodies and high sensitive immunoassay methods LY96, FAM83B, FAM162A MAPT 4488/4885L3MBTL1 1380/4885CRHBP 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.